Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

Pioglitazone Prevents Conversion to Diabetes Among Insulin-Resistant Patients: Presented at ADA By Ed Susman SAN FRANCISCO -- June 11, 2008 -- Patients with impaired glucose tolerance treated with pioglitazone were able to stave off conversion to type 2 diabetes by 81% when compared with individuals who received placebo, according to long-term results of a phase 3 trial presented here at the American Diabetes Association (ADA) 68th Scientific Sessions. In a late-breaking oral presentation here on June 9, Ralph A. DeFronzo, MD, Diabetes Division, University of Texas Health Science Center, San Antonio, San Antonio, Texas, presented data from the Actos Now Study for the Prevention of Diabetes (ACT NOW). The prospective, double-blind, placebo-controlled study examined whether pioglitazone can reduce the incidence of type 2 diabetes in patients with impaired glucose tolerance at high risk of diabetes. To be included in this study, subjects needed to have had a 2-hour plasma glucose between 140 and 199 mg/dL during a single oral glucose tolerance test. The researchers screened 1,850 subjects and identified 602 individuals with impaired glucose tolerance -- 407 had impaired fasting glucose as well as impaired glucose tolerance, and 195 subjects had isolated impaired glucose tolerance. ACT NOW subjects were recruited over a 2-year period, and then followed for 2 years after the last patient was recruited, meaning that some patients were followed for up to 4 years, Dr. DeFronzo noted. The definition of conversion to type 2 diabetes was based on a fasting glucose measurement of 126 mg/dL or higher on follow-up for a 2-hour oral glucose tolerance test measurement of 200 mg/dL or higher, plus confirmation with a second oral glucose tolerance test. The researchers assigned 299 patients to placebo and 303 subjects to pioglitazone. About 60% of the subjects were women, and nearly 75% were white. The mean age was 52 years; subjects had a mean body mass index of 34. The conversion to type 2 diabetes in placebo subjects occurred at a rate of 6.8% per year, while the rate for subjects on pioglitazone was 1.5% per year, translating to a highly significant relative risk reduction of 81% (P < .00001). Overall, 45 of the placebo patients converted to type 2 diabetes, compared with 10 in the pioglitazone group. Dr. DeFronzo reported that only 84 of the placebo patients normalised their glucose tolerance (28% of the group) compared with 127 individuals on pioglitazone (42%), which also was statistically significant (P < .001). In terms of adverse events, pioglitazone subjects experienced more oedema (22%) than did placebo subjects (15%). Also, 15 patients in the placebo group experienced cardiac events compared with 12 among the pioglitazone subjects. One sudden death occurred in each group. "Pioglitazone treatment of subjects with impaired glucose tolerance was both safe and efficacious during the 4-year study," Dr. DeFronzo said. Funding for this study was provided by Takeda Pharmaceuticals North America, Inc. [Presentation title: ACTos NOW for the Prevention of Diabetes (ACT NOW) Study.] E-mail this page to a friend or colleague! To print, use this version